SPC388

Lungnahnettlu-fjölsykru samtengt bóluefni (15-gilt, aðsogið) sem er svifblanda af hjúpuðum fjölsykrum úr S. Pneumoniae sermigerðum 1, 2, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F og 33F sem er samtengt við CRM197 burðarprótín

  • Status:
    Veitt
  • Application date:
    10.6.2022
  • Application published:
    15.7.2022
  • Grant published:
    15.3.2025
  • Max expiry date:
    18.4.2032
  • Medicine name:
    Vaxneuvance
  • Medicine for children:
    No

Timeline

Today
10.6.2022Application
15.7.2022Publication
15.3.2025Registration
18.4.2032Expires

Marketing license

  • IS authorization number:
    EU/1/21/1591/001-006
  • Date:
    31.12.2021
  • Foreign authorization number:
    EU/1/21/1591
  • Date:
    13.12.2021

Owner

  • Name:
    Wyeth LLC
  • Address:
    66 Hudson Boulevard East, New York, NY 10001-2192 US

Agent

  • Name:
    Árnason Faktor ehf.
  • Address:
    Guðríðarstíg 2-4, 113 Reykjavík

Patent

Deadlines

TypeDeadline until

Type: Frestur til að fara yfir drög að vottorði

Deadline until: 01.01.1

Upload documents